| Metric | Value ($ M) | Q2 FY25 | Q3 FY24 |
|---|---|---|---|
| Revenue | 311.31 | 5.8% | 9.1% |
| Total Income | 311.31 | 5.8% | 9.1% |
| Expenditure | 238.38 | 13.4% | 16.3% |
| PBT | 72.94 | 285.9% | 70.6% |
| Net Profit | 48.40 | 508.0% | 184.7% |
| OPM | — | ||
| NPM | 15.55% | 12.84pp | 9.59pp |
| EPS | 0.17 | 466.7% | 183.3% |
Sotera Health Reports Q3 2025 Net Revenues Up 9.1% to $311 Million
04 May 2026 · 4 May, 8:10 am
Summary
Sotera Health Company reported a 9.1% increase in net revenues for Q3 2025, reaching $311 million. Net income significantly improved to $48 million, or $0.17 per diluted share, compared to $17 million in the same quarter of the previous year. Adjusted EBITDA also saw a substantial increase of 12.2%, amounting to $164 million. Based on year-to-date performance, the company is raising its Adjusted EBITDA growth outlook for 2025 while reaffirming its net revenue outlook.
Key Highlights
- 1
Net revenues for Q3 2025 increased by 9.1% to $311 million compared to Q3 2024.
- 2
Net income for Q3 2025 was $48 million, or $0.17 per diluted share, compared to $17 million, or $0.06 per diluted share in Q3 2024.
- 3
Adjusted EBITDA for Q3 2025 increased 12.2% to $164 million compared to Q3 2024.
- 4
Adjusted EPS for Q3 2025 increased by $0.09 to $0.26 compared to Q3 2024.
- 5
For the first nine months of 2025, net revenues increased 6.2% to $860 million compared to the same period in 2024.
- 6
The company is raising its 2025 Adjusted EBITDA growth range to 6.75% - 7.75% and reaffirming its net revenues outlook range of 4.5% - 6.0%, on a constant currency basis.
Management Comments
Michael B. Petras
Jr.
Today, we reported strong top-line revenue growth and double-digit Adjusted EBITDA growth, with approximately 150 basis points of margin expansion. Based on our year-to-date performance and good visibility into the remainder of this year, we are reaffirming our 2025 revenue outlook and raising our Adjusted EBITDA outlook.
Informational and educational content only. Not investment advice.